Business Wire

Genesis Q1 2022 Report Reflects Another Strong Quarter Amid Market Uncertainty

29.4.2022 16:15:00 EEST | Business Wire | Press release

Share

Genesis, a digital asset industry pioneer and digital currency prime brokerage, today released its Q1 2022 Market Observations Report, highlighting major trends across institutional digital asset markets. The report provides a breakdown of Genesis’ lending, derivatives, spot, and custody activities across Q1 2022, along with in-depth insight from the Genesis lending and derivatives desks on trends such as the growing adoption of permissioned DeFi protocols, the gradual institutionalization in debt markets and the continued growing interest from the traditional financial community in stablecoin derivatives.

The first quarter was characterized by Genesis’ notable growth across most of its operations – including another record quarter in derivatives trading activity – even against the backdrop of lower overall crypto market volumes and high levels of uncertainty throughout most asset types. Highlights during the quarter include the following:

  • In Q1 2022, the USD amount of active loans outstanding grew to $14.6 billion against declining prices, a level 17% higher than at the end of the previous quarter, and 62% higher than at the end of Q1 2021.
  • As of March 31, cumulative loan originations had reached $195 billion.
  • The notional volume traded by the derivatives desk in Q1 reached $27.8 billion, up 33% from Q4, inclusive of negotiated block- and exchange- traded futures.
  • Assets under custody increased by 23% over Q1.
  • The USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% vs Q4 2022.
  • Genesis’ headcount increased 22% over the quarter to reach 208 employees across three continents.

“Institutions continue to develop their crypto strategies and strengthen their understanding of this industry, even amid the market uncertainty that has marked the start to this year,” said Michael Moro, CEO of Genesis. “As we continue to deepen engagement with our clients across Genesis’ wide range of products, we are committed to further expanding our market share and delivering innovative strategies for clients to access this growing asset class.”

Derivatives and Spot Trading

Genesis saw another record quarter in derivatives trading activity, with over $27.8 billion in notional value traded globally. This figure includes bilateral OTC, negotiated block futures trades and exchange-traded volumes, representing 33% quarter-on-quarter growth. In Q1, Genesis was also #1 in market share for blocked BTC and ETH Deribit-cleared derivatives via Paradigm with over $6.6 billion transacted1. The firm also printed the first ever ETH and BTC Micro options trades on the CME in March. Additionally, the Genesis derivatives desk traded 61 different assets in the first quarter, with $4.7 billion notional traded in altcoin derivatives – Genesis’ highest quarterly total yet as it continues to prove its ability to help clients hedge and take directional positions in even the most esoteric of markets.

The Genesis spot desk traded over $11.4 billion in volume in Q1, with the continuing trend toward greater diversification of assets. BTC comprised 48% of the traded volume, in line with last quarter, while ETH saw a drop from 33% to 23% of total traded volume in Q1. The Genesis spot desk also saw a notable increase in activity across assets such as LUNA, SOL, AVAX, ZEC, LINK, ATOM and GALA.

Crypto Lending

Despite a market environment faced with many uncertainties, as valuations across all crypto assets nearly halved from November peaks, the Genesis lending desk originated over $44.3 billion in loans in Q1 2022, bringing cumulative originations since inception in March 2018 to $195 billion. Active loans outstanding also climbed to $14.6 billion to close the quarter, up 17% from the end of 2021.

The strong level of activity Genesis saw in Q1 – despite the weak market environment – was mainly due to organic volume driven by new institutions entering the industry and by increasing demand for cash loans, which allowed Genesis to capitalize on its core competitive strengths as a leading digital asset prime broker.

Custody

Assets under custody increased by 23% quarter-on-quarter, while the USD volume of assets moved from Genesis Custody to the Genesis trading or lending desks increased by 141% over the same period. This comes as Genesis continues to integrate its lending and trading desks more tightly into its SOC 2 Type 1-audited and FCA-registered custodian.

The number of customers onboarded to Genesis Custody also increased by 36% over the quarter, driven mainly by large public and private mining companies, venture capital firms and other traditional asset managers on a global level, following Genesis’ FCA registration and the roll out of its 24/5 support.

The Genesis Q1 2022 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q1 2022 Market Observations Report, click here.

About Genesis

Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.

The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.

Genesis is a wholly owned subsidiary of Digital Currency Group (DCG), one of the largest private investors in blockchain and digital asset companies.

For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.

____________________________
1 Per Paradigm statistics as of April 28, 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marc Yaklofsky
press@genesistrading.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye